In silico assessment revealed differences in receptor binding of neuromuscular blocking agents and fluoroquinolones, indicating key structural features.
In contrast to fluoroquinolones, NMBAs displayed different affinity for MRGPRX2. Cellular responses in bench experiments closely reflected the MD predictions. Alanine scanning revealed that the MRGPRX2 binding pocket exhibits low susceptibility to single-site mutations that enhance receptor responsiveness.
No takes yet. Share an insight, caveat, or question.
Rybka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: